After Biogen management presented more detailed aducanumab data at the CTAD medical meeting yesterday, Morgan Stanley analyst Matthew Harrison said he does not view the cumulative data presented as significantly different from the data previously presented and he thinks the presentation is unlikely to shift the debate in favor of either bulls or bears. Harrison maintains an Underweight rating and $262 price target on Biogen shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here